Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human proof-of-concept trial of NM-136 in Prader-Willi Syndrome

Next Previous
Trial Profile

First-in-human proof-of-concept trial of NM-136 in Prader-Willi Syndrome

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NM-136 (Primary)
  • Indications Obesity; Prader-Willi syndrome
  • Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

  • 05 Apr 2023 According to a 9 Meters Biopharma media release, the company expect to initiate this study as early as late this year.
  • 05 Apr 2023 According to a 9 Meters Biopharma media release, company announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting and plans to submit an IND to the FDA in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting this study in the U.S.
  • 20 Oct 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top